Merck Stock Hits New 52-Week High: What's Driving the Rally?
MRK hits a 52-week high as positive melanoma data, pipeline progress, new launches and M&A bolster its long-term growth outlook.
MRK - Merck & Co., Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$154.93
DETAILS
HIGH:
$180.00
LOW:
$105.00
MEDIAN:
$150.00
CONSENSUS:
$154.93
UPSIDE:
1.16%
Stock News
Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus
VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.
Beverly Hills Private Wealth LLC Cuts Stock Holdings in Merck & Co., Inc. $MRK
Beverly Hills Private Wealth LLC cut its stake in shares of Merck and Co., Inc. (NYSE: MRK) by 59.7% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,600 shares of the company's stock after selling 8,299 shares during
Merck & Co., Inc. $MRK Shares Acquired by BlackRock Inc.
BlackRock Inc. increased its position in Merck and Co., Inc. (NYSE: MRK) by 0.5% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 226,999,837 shares of the company's stock after purchasing an additional 1,073,507 shares during the period. BlackRock Inc. owned 9.19% of Merck and
Merck Just Gained 19% in a Month. What Would It Take to Get MRK Stock Up to $200?
The setup around Merck (NYSE:MRK | MRK Price Prediction) shares heading into September is unusual for a mega-cap pharma.
3 Dividend Stocks to Hold for the Next 10 Years
These healthcare leaders are unlikely to suspend their dividend programs.
Explainer: How the Merck/Moderna cancer vaccine works and possible barriers to wide use
The personalized cancer vaccine being developed by Moderna and Merck has boosted hopes that mRNA technology could open up a new avenue of treatment, but the available evidence is still limited.
What Happens if Moderna's Cancer Vaccine Works
Moderna and Merck's personalized cancer vaccine could transform cancer treatment and create a multibillion-dollar market, but investors may already be pricing in much of its potential.
“Give Me Anything But Tech”: Jim Cramer's Bold Call on the Market's Next Big Rotation
On CNBC's Squawk on the Street Monday morning, Jim Cramer said the tape has soured on the trade that carried the market for most of the past year.
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.
Bank of New York Mellon Corp Sells 373,190 Shares of Merck & Co., Inc. $MRK
Bank of New York Mellon Corp lowered its stake in Merck and Co., Inc. (NYSE: MRK) by 2.0% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,340,173 shares of the company's stock after selling 373,190 shares
Bellars Harris Wealth Management LLC Makes New $10.26 Million Investment in Merck & Co., Inc. $MRK
Bellars Harris Wealth Management LLC bought a new position in shares of Merck and Co., Inc. (NYSE: MRK) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 79,847 shares of the company's stock, valued at approximately $10,260,000. Merck
Chase Investment Counsel Corp Buys 3,591 Shares of Merck & Co., Inc. $MRK
Chase Investment Counsel Corp grew its position in Merck and Co., Inc. (NYSE: MRK) by 57.7% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,815 shares of the company's stock after purchasing an additional 3,591 shares during the period. Chase Investment Counsel Corp's
CORDA Investment Management LLC. Has $53.99 Million Holdings in Merck & Co., Inc. $MRK
CORDA Investment Management LLC. lessened its stake in shares of Merck and Co., Inc. (NYSE: MRK) by 1.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 420,154 shares of the company's stock after selling 7,372 shares during the quarter. Merck and
Global Retirement Partners LLC Acquires New Stake in Merck & Co., Inc. $MRK
Global Retirement Partners LLC bought a new position in shares of Merck and Co., Inc. (NYSE: MRK) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 78,760 shares of the company's stock, valued at approximately $10,121,000. Other hedge funds and
Focus Partners Advisor Solutions LLC Sells 11,635 Shares of Merck & Co., Inc. $MRK
Focus Partners Advisor Solutions LLC trimmed its position in Merck and Co., Inc. (NYSE: MRK) by 11.9% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 86,089 shares of the company's stock after selling 11,635 shares during the period. Focus Partners Advisor Solutions LLC's holdings
Merck & Co., Inc. $MRK Shares Sold by ABN AMRO Bank N.V.
ABN AMRO Bank N.V. reduced its position in Merck and Co., Inc. (NYSE: MRK) by 7.6% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 136,228 shares of the company's stock after selling 11,149 shares during the quarter. ABN AMRO Bank
Moderna Sinks 7% as Traders Book Profits on a 392% Year-to-Date Surge; BioNTech Drops 4%, Merck Slips
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 7% to $135.22 in Monday morning trading, cooling off after one of the most explosive runs in biotech this year.
111 Capital Buys Shares of 4,582 Merck & Co., Inc. $MRK
111 Capital purchased a new stake in Merck and Co., Inc. (NYSE: MRK) during the second quarter, according to its most recent filing with the SEC. The firm purchased 4,582 shares of the company's stock, valued at approximately $589,000. Several other hedge funds also recently bought and sold shares of the company. Kingdom
Weekend Morning Brew: Major Trials, Earnings, and Regulatory Changes Impact Markets
Weekly Market HighlightsDuring the week, 828 stocks gained more than 10%, while 722 stocks declined by more than 10%, indicating significant volatility in the
Price Targets
Merck price target raised to $170 from $145 at Argus
$170.00
(was $153.61)
Jasper Hellweg
·
Argus Research
Merck price target raised to $180 from $155 at Wolfe Research
$180.00
(was $150.69)
Alexandria Hammond
·
Wolfe Research
Merck price target raised to $160 from $140 at Goldman Sachs
$160.00
(was $149.25)
Goldman Sachs
Merck price target raised to $170 from $142 at BMO Capital
$170.00
(was $149.65)
BMO Capital
Merck price target raised to $175 from $145 at UBS
$175.00
(was $152.22)
UBS
Merck downgraded to Sector Perform from Outperform at RBC Capital
$150.00
(was $152.22)
RBC Capital
UBS Downgrades Merck (MRK) to Neutral
$150.00
(was $152.22)
Matthew Weston
·
UBS
Merck upgraded to Overweight from Equal Weight at Morgan Stanley
$179.00
(was $152.22)
Morgan Stanley
Daiwa upgrades Merck to Outperform on pipeline success
$143.00
(was $130.45)
Daiwa
Merck (MRK) PT Raised to $145 at Argus
$145.00
(was $130.90)
Jasper Hellweg
·
Argus Research
Merck price target raised to $116 from $113 at Morgan Stanley
$116.00
(was $130.40)
Terence Flynn
·
Morgan Stanley
Merck price target raised to $146 from $145 at Guggenheim
$146.00
(was $128.04)
Vamil Divan
·
Guggenheim
Merck price target raised to $150 from $140 at Barclays
$150.00
(was $131.84)
Emily Field
·
Barclays
Merck (MRK) PT Raised to $105 at Bernstein SocGen Group
$105.00
(was $132.34)
Courtney Breen
·
Bernstein
Merck (MRK) PT Raised to $142 at BMO CapitalMember Login
$142.00
(was $124.08)
BMO Capital
Merck (MRK) PT Raised to $145 at Guggenheim
$145.00
(was $123.54)
Vamil Divan
·
Guggenheim
Merck price target raised to $150 from $135 at HSBC
$150.00
(was $126.05)
Rajesh Kumar
·
HSBC
Merck (MRK) PT Raised to $141 at BofA Securities
$141.00
(was $129.38)
Jefferies
Merck price target raised to $155 from $136 at Scotiabank
$155.00
(was $129.38)
Scotiabank
Guggenheim Reiterates Buy Rating on Merck (MRK)
$140.00
(was $115.21)
Vamil Divan
·
Guggenheim